Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.
“Chemoablation of metastatic melanoma with rose bengal (PV-10)”
Dr. Sanjiv Agarwala, Chief, Medical Oncology and Hematology at St. Luke’s Hospital and Health Network in Bethlehem, PA, and Principal Investigator for Provectus’s Phase 2 PV-10 trial site at St. Luke’s, will present Abstract #8534, entitled “Chemoablation of metastatic melanoma with rose bengal (PV-10),” in the General Poster Session.
Dr. Agarwala said, “With enrollment of all 80 subjects this multi-center Phase 2 trial completed in May 2009, I look forward to presenting a comprehensive update on PV-10 for treatment of metastatic melanoma. As I recently noted, PV-10 is intriguing to me as an oncologist because it appears to recruit immune cells to the ablation site, leading to the potential of a systemic benefit.”
Craig Dees, PhD, CEO of Provectus said, “We look forward to Dr. Agarwala’s presentation, which marks another milestone for the continued research and development of PV-10 as we gain more momentum in our fight against cancer. Metastatic melanoma is a dreadful and deadly disease, and we believe PV-10 holds promise as a viable, safe and effective treatment, with minimal side effects, not only for this disease, but potentially for a broad spectrum of other cancers as well.”
Source Provectus Pharmaceuticals, Inc. (www.pvct.com)